China Resources Pharmaceutical Group (FRA:640) EV-to-Revenue : 0.39 (As of Mar. 02, 2025)

China Resources Pharmaceutical Group EV-to-Revenue Chart

China Resources Pharmaceutical Group Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-Revenue		Get a 7-Day Free Trial					0.37	0.28	0.28	0.33	0.32

China Resources Pharmaceutical Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EV-to-Revenue	Get a 7-Day Free Trial															-	0.33	-	0.32	-

Competitive Comparison of China Resources Pharmaceutical Group's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Pharmaceutical Group's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's EV-to-Revenue falls into.

China Resources Pharmaceutical Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

China Resources Pharmaceutical Group's EV-to-Revenue for today is calculated as:

China Resources Pharmaceutical Group's current Enterprise Value is €12,440 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €32,121 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group  (FRA:640) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

China Resources Pharmaceutical Group's PS Ratiofor today is calculated as:

China Resources Pharmaceutical Group's share price for today is €0.655.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was €5.11.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group Business Description